Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus NAQUA.
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azilsartan medoxomil is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Chlorthalidone is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing sodium and water excretion.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg or 25 mg orally once daily; maximum dose: azilsartan medoxomil 40 mg/chlorthalidone 25 mg per day.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Azilsartan medoxomil: Terminal half-life approximately 11 hours. Chlorthalidone: Long terminal half-life of 40-60 hours (mean 47 hours), allowing once-daily dosing.
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Azilsartan medoxomil: Approximately 55% of the dose is excreted in feces and 42% in urine, mostly as metabolites. Chlorthalidone: Primarily excreted unchanged in urine (50-70%) via tubular secretion; approximately 30% is excreted in feces via biliary elimination.
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic